Epstein Secrets

From To: Lesley Groff Subject: Re: Catching Up Date: Thu, 17 Jan 2019 17:26:03 +0000 Inline-Images: 1506365439123blobjpg Great. Thanks so much Lesley! thoHebe LLL ce

From To: Lesley Groff Subject: Re: Catching Up Date: Thu, 17 Jan 2019

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US

From: Lesley Groff To: Jefffrey Epstein <[email protected]>, Ri

From: Lesley Groff To: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: Date: Thu, 17 Jan 2019 17:19:49 +0000 Inline-Images: 1506365439123blobjpg; 150

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US

To: rnYahoo•conll From: Lesley Groff Sent Thur 1/17/2019 5:18:48 PM Subject: Re: Catching Up HI ...all is good! I will forward this on for you... Hope all is well with you too. Le

To: rnYahoo•conll From: Lesley Groff Sent Thur 1/17/2019 5:18:48 PM Subject: Re: Ca

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U

[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:49 PM Subject: Fo

To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:49 PM Subject: Fo From: < r t oksjaySsam a > To: jeevacation@gmaitcom <jeevacationeinmait.com>; I requested I f

ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that EFTA_R1_01089814 EFTA02275773 reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly

To: Lesley Groff( From: Richard Kahn Sent subsa Thu PM . Re: i will mention to jee when we speak next thanks Richard Kahn HBRK Associates Inc. 575 Lexingt

To: Lesley Groff( From: Richard Kahn Sent subsa Thu PM . Re

cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U

To: Richard Kahn From: Lesley Groff Subject ThuWWI PM Re: I I Thx Sent from my iPhone On Jan 17, 2019, at 3:50 PM, Richard Kahn <richardkahn I [email protected]> wrote: i will mentio

To: Richard Kahn From: Lesley Groff Subject ThuWWI PM Re: I I Thx Sent from my

cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the

From: Lesley Groff <-> Sent: Thursday, January 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the below 'catch =p' email. = c

From: Lesley Groff <-> Sent: Thursday, January 17, 2019 5:20 PM T

ical industry to shift their focus from addressing =ymptoms of disease to fundamental evolutionary shortfalls. So far, I placed a =enetic vector at the National Institute of Medicine in France (that =eversed glaucoma in mice using the neuroglobin gene) under formal =icence review with a publicly traded pharma group here in the US